San Diego, CA (Press Release) – Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported today that Genmab A/S announced plans for a Phase 1 clin­i­cal trial of a sub­cu­tane­ous formulation of the anti-CD38 anti­body dara­tu­mu­mab using the ENHANZE™ tech­nol­o­gy. In December 2014, Janssen Biotech, Inc. (Janssen) entered into an agree­ment with Halozyme Therapeutics for the pur­pose of devel­op­ing and com­mer­cializing prod­ucts combining pro­pri­e­tary Janssen com­pounds with Halozyme's ENHANZE tech­nol­o­gy. This agree­ment has the poten­tial to lead to the devel­op­ment of a sub­cu­tane­ous formulation of dara­tu­mu­mab. Dara­tu­mu­mab is being developed under a col­lab­o­ration between Janssen and Genmab A/S since August 2012 when Genmab granted Janssen an exclusive world­wide license to develop, manu­fac­ture, and com­mer­cial­ize dara­tu­mu­mab.

About Dara­tu­mu­mab

Daratumumab, a human mono­clonal anti­body that targets CD38 on the surface of multiple myeloma cells, is in clin­i­cal devel­op­ment as a single agent and in com­bi­na­tion with standard of care ther­a­pies in several settings of multiple myeloma. Dara­tu­mu­mab may also have poten­tial in other hema­to­logic malig­nan­cies in which CD38 is expressed, in­­clud­ing non-Hodgkins lym­phoma and various leukemias.

About ENHANZE™

ENHANZE™ is Halozyme's pro­pri­e­tary drug delivery plat­form based on the Company's patented re­com­bi­nant human hyaluronidase enzyme (rHuPH20). rHuPH20 has been shown to remove traditional limitations on the volume of biologics that can be delivered sub­cu­tane­ously (just under the skin). By using rHuPH20, some biologics and com­pounds that are admin­istered in­tra­venously may instead be delivered sub­cu­tane­ous­ly. This delivery has been shown in studies to reduce health care practitioner time required for ad­min­is­tra­tion and shorten time for drug admin­istra­tion. ENHANZE may also benefit sub­cu­tane­ous biologics by reducing the need for multiple injections.

About Halozyme

Halozyme Therapeutics is a bio­tech­nol­o­gy com­pany focused on devel­op­ing and com­mer­cial­iz­ing novel on­col­o­gy ther­a­pies that target the tumor microenvironment. Halozyme's lead pro­pri­e­tary pro­gram, our in­ves­ti­ga­tion­al drug PEGPH20, applies a unique ap­proach to targeting solid tumors, allowing in­­creased access of co-administered cancer drug ther­a­pies to the tumor. PEGPH20 is cur­rently in devel­op­ment for meta­static pan­cre­atic cancer and non-small cell lung cancer and has poten­tial across addi­tional cancers in com­bi­na­tion with dif­fer­en­t types of cancer ther­a­pies. In addi­tion to its pro­pri­e­tary prod­uct portfolio, Halozyme has es­tab­lished value-driving part­ner­ships with leading pharma­ceu­tical com­pa­nies in­­clud­ing Roche, Pfizer, Janssen and Baxter for its drug delivery plat­form, ENHANZE™, which enables biologics and small molecule com­pounds that are cur­rently admin­istered in­tra­venously to be delivered sub­cu­tane­ously. Halozyme is head­quar­tered in San Diego, CA. For more in­for­ma­tion on how we are innovating, please visit our corporate web­site at www.halozyme.com.

Safe Harbor Statement

In addi­tion to historical in­for­ma­tion, the state­ments set forth above in­clude forward-looking state­ments (in­clud­ing, without limitation, state­ments concerning the devel­op­ment and com­mer­cial­iza­tion of prod­uct can­di­dates (including those under the Halozyme-Janssen col­lab­o­ration), the poten­tial benefits and attributes of such prod­uct can­di­dates) that involve risk and un­cer­tain­ties that could cause actual results to differ materially from those in the forward-looking state­ments. The forward-looking state­ments are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "antic­i­pate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the ex­pec­ta­tions con­tained in forward-looking state­ments as a result of several factors, in­­clud­ing unexpected results or delays in devel­op­ment and regu­la­tory review, regu­la­tory approval requirements, unexpected adverse events, competitive con­di­tions and the con­tin­u­a­tion of the Halozyme-Janssen and other col­lab­o­rations. These and other factors that may result in dif­fer­ences are discussed in greater detail in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Com­mis­sion on March 2, 2015.

Source: Halozyme.